# Sodium Thiosulfate to Preserve Cardiac Function in STEMI

Study · id `cardio:ct-nct02899364` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02899364](<https://clinicaltrials.gov/study/NCT02899364>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02899364

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 380 participants.

## Technical summary

Registry record NCT02899364. Randomized; triple masking; primary purpose prevention. Start 2018-07-20 (actual); primary completion 2021-06-25 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 380 participants (planned count; ClinicalTrials.gov record NCT02899364, source copy `cardio:ctgov-nct02899364-2021-09-09`, retrieved 2026-10-26)
- Started: 2018-07-20 (actual) (ClinicalTrials.gov record NCT02899364, source copy `cardio:ctgov-nct02899364-2021-09-09`, retrieved 2026-10-26)
- Primary completion: 2021-06-25 (actual) (ClinicalTrials.gov record NCT02899364, source copy `cardio:ctgov-nct02899364-2021-09-09`, retrieved 2026-10-26)
- Completion: 2023-03 (anticipated) (ClinicalTrials.gov record NCT02899364, source copy `cardio:ctgov-nct02899364-2021-09-09`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT02899364, source copy `cardio:ctgov-nct02899364-2021-09-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02899364-2021-09-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sodium Thiosulfate to Preserve Cardiac Function in STEMI
- Acronym: GIPS-IV
- Condition: Myocardial Infarction
- Condition: Heart Failure
- Intervention (Drug): Sodium thiosulfate
- Intervention (Drug): Sodium chloride 0.9%
- Intervention (Procedure): primary percutaneous coronary intervention
- Intervention (Other): cardiac magnetic resonance imaging
- Lead sponsor: University Medical Center Groningen
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: University Medical Center Groningen (`cardio:org-university-medical-center-groningen`)

## Provenance

Content hash: cd7a3eb49ddcdafbcd72fcd15f0fec87d4725b74f24b223ebc6b77fdc7689a71
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
